Dr Jorg Taubel attending ACCP in San Diego

Posted:

September 2017

Dr Jorg Taubel will be attending the ACCP in San Diego, September 17-19, where he will be discussing his latest poster publications ‘The 24 Hour Profile of Moxifloxacin Effect on QTc – A Reflection of Diurnal Variations'

Back to news

More about us Adaptive Phase I & IIa Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020

Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.

View event

COVID-19 – External Monitoring Guidelines

July 1, 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

First transdermal patch to treat schizophrenia hits market

March 18, 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

Statement: COVID-19

March 23, 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.